 |
市場調査レポート
商品コード
1321932
核医学の世界市場 (2023-2030年)：製品タイプ (診断 (SPECT・PECT)・治療 (αエミッター・βエミッター))・用途 (心臓病・神経・腫瘍) 別の規模・シェア・成長分析・予測Global Nuclear Medicine Market Size, Share, Growth Analysis, By Product type(Diagnostic (SPECT AND PECT), Therapeutic (Alpha Emitters and Beta Emitters)), By Application(Cardiology Neurology, Oncology) - Industry Forecast 2023-2030 |
||||||
| 核医学の世界市場 (2023-2030年)：製品タイプ (診断 (SPECT・PECT)・治療 (αエミッター・βエミッター))・用途 (心臓病・神経・腫瘍) 別の規模・シェア・成長分析・予測 |
|
出版日: 2023年07月16日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
世界の核医学の市場規模は、2021年の81億米ドル、2022年の89億米ドルから、予測期間中は13%のCAGRで推移し、2030年には244億米ドルの規模に成長すると予測されています。
核医学の市場は、強力な製品パイプラインと、こうした技術へのアクセス強化を目的とした政府の支援イニシアティブにより成長を遂げています。COVID-19の影響にもかかわらず、必須医薬品の製造に重要な役割を果たす原子炉は、厳格な安全対策を講じながら操業を継続しています。前立腺癌は、特に高齢男性の罹患率が高く、重大な懸念事項ですが、最近、転移性前立腺癌の治療薬としてPluvicto (177Lu-PSMA-617) が米国FDAから承認されました。これは、核医学の進歩をさらに強調するものです。
癌と心血管疾患の罹患率と有病率の増加は、核医学市場の拡大を促進する主な要因です。これらの疾患は早期発見・早期治療によって予防できることが多く、核医学が重要な役割を果たしています。世界保健機関（WHO）によると、2020年の死亡原因の第1位は癌であり、2025年にかけて症例数は増加すると予測されています。同様に、心血管系疾患は2019年に世界の死因の多くを占め、2030年までにさらに増加すると予測されています。これらの疾患の診断と治療における核医学の活用が市場の大幅な成長につながります。核画像診断モダリティ、特にPET/PET-CTの技術的進歩は、その用途を腫瘍だけでなく、心臓病、神経、感染症検出などの分野にも拡大しています。早期診断と疾患管理の改善がもたらす好影響に対する認識の高まりが市場成長をさらに後押しし、PETとSPECTの処置件数の増加をもたらしています。
当レポートでは、世界の核医学の市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、法規制環境、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。
目次
エグゼクティブサマリー
調査手法
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資分析
- 主要成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーターの分析
- 将来のディスラプションに関するSkyquestの特別な洞察
世界の核医学市場：製品タイプ別
- 市場概要
- 診断 (SPECT・PECT)
- 治療 (αエミッター・βエミッター)
- 小線源治療
世界の核医学市場：用途別
- 市場概要
- 循環器神経科
- 腫瘍
- 甲状腺
- リンパ腫
- 骨転移
- 内分泌腫瘍
- その他
世界の核医学市場：地域別
- 市場概要
- 北米
- 欧州
- アジア太平洋
- ラテンアメリカ
- 中東・アフリカ
競合情勢
- トップ5社の比較
- 主要企業の市場での位置付け
- 主要企業の採用戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア
主要企業プロファイル
- GE Healthcare
- Siemens Healthineers
- Philips Healthcare
- Curium Pharma
- Cardinal Health
- Bracco Imaging
- Eckert &Ziegler
- Lantheus Medical Imaging
- Jubilant Life Sciences
- Nordion Inc.
- IBA Molecular
- Advanced Accelerator Applications (AAA)
- Progenics Pharmaceuticals
- Norgine BV
- FUJIFILM Holdings Corporation
- Bayer Healthcare
- Theragnostics
- RadioMedix Inc.
- Ion Beam Applications SA (IBA)
- Novartis AG
Global Nuclear Medicine Market size was valued at USD 8.1 billion in 2021 and is poised to grow from USD 8.9 billion in 2022 to USD 24.4 billion by 2030, growing at a CAGR of 13% in the forecast period (2023-2030).
Nuclear medicine is a specialized field within radiology that utilizes small amounts of radioactive materials to examine organ structure and function. It combines various disciplines such as chemistry, physics, mathematics, computer technology, and medicine. This branch of radiology is particularly valuable in diagnosing and treating diseases at early stages, such as thyroid cancer. While standard X-rays have limitations in visualizing soft tissues, nuclear medicine imaging enables clearer visualization of organs and tissues. The market for nuclear medicine is experiencing growth due to a robust product pipeline and supportive government initiatives aimed at enhancing access to these technologies. Despite the impact of the COVID-19 pandemic, nuclear reactors, which play a critical role in producing essential medicines, have continued operations with stringent safety measures. Prostate cancer is a significant concern, with high incidence rates, particularly among older men. The recent approval of Pluvicto (177Lu-PSMA-617) by the U.S. FDA for the treatment of metastatic prostate cancer further underscores the advancements in nuclear medicine.
Segments covered in this report:
Global nuclear medicine market has been segmented based on product type, application, end use, procedure, and region. Based on product type, global nuclear medicine market are further sub-segmented into diagnostic (SPECT and PET), therapeutic (alpha emitters and beta emitters), and brachytherapy. On the basis of application, global nuclear medicine market is segmented into cardiology neurology, oncology, thyroid, lymphoma, bone metastasis, endocrine tumour, and others. According to end use, global nuclear medicine market is segmented into hospitals & clinics, diagnostic centers and others. By procedure, the market is segmented into central nervous system, endocrine, skeletal, gastrointestinal, genito-urinary, pulmonary. By region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and MEA.
Driver
The increasing incidence and prevalence of cancer and cardiovascular disease are key factors driving the expansion of the nuclear medicine market. These diseases can often be prevented through early detection and treatment, where nuclear medicine plays a crucial role. According to the World Health Organization (WHO), cancer was the leading cause of death in 2020, with an expected rise in new cases worldwide by 2025. Similarly, cardiovascular disease accounted for a significant number of global deaths in 2019, with projections indicating a further increase by 2030. The utilization of nuclear medicine in diagnosing and treating these conditions positions it for significant market growth. Technological advancements in nuclear imaging modalities, particularly PET/PET-CT, have expanded its applications beyond oncology to areas like cardiology, neurology, and infection detection. The increased awareness of the positive impact of early diagnosis and improved disease management further drives market growth, resulting in a rise in PET and SPECT procedures.
Restraint
The growth of the nuclear medicine imaging market is expected to be restrained in the coming years due to the increasing adoption of alternative diagnostic options such as MRI and CT scans. These alternatives are more cost-effective compared to nuclear medicines, leading to their greater use, especially in developing nations. Moreover, reimbursement policies favor the utilization of MRI and CT scans, further hindering the market for nuclear medicine. Additionally, the high cost associated with nuclear imaging systems and procedures, along with the extensive use of CT and MRI scans annually, pose a risk to the volume of PET-CT procedures.
Key Market Trend
The market for nuclear medicine therapies is witnessing a focus on development by companies, driven by the clinical benefits of this treatment option compared to others. The demand for nuclear medicine therapies is expected to rise globally, supported by the positive outcomes observed in the treatment of cancer and other disorders. This is particularly significant in countries with a high cancer burden. For instance, Curium received FDA approval to initiate a Phase-III trial for lutetium Lu 177 PSMA I&T, a radiopharmaceutical targeting Prostate-Specific Membrane Antigen (PSMA). Many market participants are also actively developing new therapeutic products for various medical conditions, contributing to the growth of the market.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Nuclear Medicine Market by Product type
- Market Overview
- Diagnostic (SPECT AND PECT)
- Therapeutic (Alpha Emitters and Beta Emitters)
- Brachytherapy
Global Nuclear Medicine Market by Application
- Market Overview
- Cardiology Neurology
- Oncology
- Thyroid
- Lymphoma
- Bone Metastasis
- Endocrine Tumor
- OthersSegmentEnd-userSub-SegmentsHospitals & Clinics
- Diagnostic Centers and OthersSegmentProcedureSub-SegmentsCentral Nervous System
- Endocrine
- Skeletal
- Gastrointestinal
- Genito-urinary
- Pulmonary
Global Nuclear Medicine Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- GE Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Philips Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Curium Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cardinal Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bracco Imaging
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eckert & Ziegler
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lantheus Medical Imaging
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jubilant Life Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nordion Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- IBA Molecular
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Advanced Accelerator Applications (AAA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Progenics Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Norgine B.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- FUJIFILM Holdings Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer Healthcare
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Theragnostics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- RadioMedix Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ion Beam Applications S.A. (IBA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
